How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?

ABSTRACT:

Background

The aims of this research were to provide a better understanding of the specific evidence needs for assessment of clinical and cost-effectiveness of cell and gene therapies, and to explore the extent that the relevant categories of evidence are considered in health technology assessment (HTA) processes.

Methods

A targeted literature review was conducted to identify the specific categories of evidence relevant to the assessment of these therapies. Forty-six HTA reports for 9 products in 10 cell and gene therapy indications across 8 jurisdictions were analysed to determine the extent to which various items of evidence were considered.

Results

The items to which the HTA bodies reacted positively were: treatment was for a rare disease or serious condition, lack

SUBMITTER: Drummond M 

PROVIDER: S-EPMC10182681 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature